Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study

Publication | Open Access

DOI Full Paper Access

129

Citations

References

2017

Year

Annalisa Chiappella, Maurizio Martelli, Emanuele Angelucci, Ercole Brusamolino, Andrea Evangelista, Angelo Michele Carella, Caterina Stelitano, Giuseppe Rossi, Monica Balzarotti, Francesco Merli,

The Lancet Oncology

Hematological MalignancyLymphoid NeoplasiaRadiation OncologyTransplantationRituximab-dose-dense ChemotherapyMedicineImmunologyPathologyHigh-dose ChemotherapyImmunotherapyOncologyCell TransplantationPhase 3